Direct Medical Costs for Patients with Type 2 Diabetes and Related Complications: A Prospective Cohort Study Based on the Korean National Diabetes Program.
10.3346/jkms.2012.27.8.876
- Author:
Tae Ho KIM
1
;
Ki Hong CHUN
;
Hae Jin KIM
;
Seung Jin HAN
;
Dae Jung KIM
;
Jiyeong KWAK
;
Young Seol KIM
;
Jeong Taek WOO
;
Yongsoo PARK
;
Moonsuk NAM
;
Sei Hyun BAIK
;
Kyu Jeung AHN
;
Kwan Woo LEE
Author Information
1. Division of Endocrinology, Department of Internal Medicine, Kwandong University College of Medicine, Myongji Hospital, Goyang, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Direct Medical Cost;
Economic Cost;
Korea;
Macrovascular Complications;
Microvascular Complications;
Diabetes Mellitus, Type 2
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Asian Continental Ancestry Group;
Cohort Studies;
Costs and Cost Analysis;
Databases, Factual;
Diabetes Mellitus, Type 2/complications/*economics;
Female;
Health Care Costs;
Humans;
Male;
Middle Aged;
Prospective Studies;
Republic of Korea;
Vascular Diseases/complications;
Young Adult
- From:Journal of Korean Medical Science
2012;27(8):876-882
- CountryRepublic of Korea
- Language:English
-
Abstract:
We analyzed the direct medical costs for Korean patients with type 2 diabetes according to the type of complications and the number of microvascular complications. We analyzed costs for type 2 diabetes and associated complications in 3,125 patients. These data were obtained from the Korean National Diabetes Program (KNDP), a large, ongoing, prospective cohort study that began in 2005. The cost data were prospectively collected, using an electronic database, for the KNDP cohort at six hospitals. The costs were analyzed according to complications for 1 yr from enrollment in the study. Among 3,125 patients, 918 patients had no vascular complications; 1,883 had microvascular complications only; 51 had macrovascular complications only; and 273 had both complications. The annual direct medical costs for a patient with only macrovascular, only microvascular, or both macrovascular and microvascular complications were 2.7, 1.5, and 2.0 times higher than the medical costs of patients without complications. Annual direct medical costs per patient increased with the number of microvascular complications in patients without macrovascular complications. The economic costs for type 2 diabetes are attributable largely to the management of microvascular and macrovascular complications. Proper management of diabetes and prevention of related complications are important for reducing medical costs.
